High Growth Tech Stocks In Hong Kong Featuring 3 Prominent Picks

The Hong Kong market has been experiencing notable volatility, with the Hang Seng Index recently declining by 3.03% amid weak corporate earnings and economic data. Despite these challenges, high-growth tech stocks in Hong Kong remain a focal point for investors seeking opportunities in an otherwise turbulent environment. When considering high-growth tech stocks, it's important to look at companies with strong fundamentals and innovative products or services that can withstand broader market pressures.

Top 10 High Growth Tech Companies In Hong Kong

Name	Revenue Growth	Earnings Growth	Growth Rating
Wasion Holdings	22.37%	25.47%	★★★★★☆
MedSci Healthcare Holdings	48.74%	48.78%	★★★★★☆
Inspur Digital Enterprise Technology	25.37%	39.10%	★★★★★☆
Cowell e Holdings	31.82%	35.43%	★★★★★★
Akeso	32.52%	55.08%	★★★★★★
Innovent Biologics	21.45%	59.82%	★★★★★☆
RemeGen	26.30%	52.19%	★★★★★☆
Sichuan Kelun-Biotech Biopharmaceutical	25.22%	9.81%	★★★★★☆
Biocytogen Pharmaceuticals (Beijing)	21.53%	109.17%	★★★★★☆
Beijing Airdoc Technology	37.47%	93.35%	★★★★★☆

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Innovent Biologics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Innovent Biologics, Inc. is a biopharmaceutical company that develops and commercializes monoclonal antibodies and other drug assets for oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases in China with a market cap of approximately HK$70.30 billion.

Operations: Innovent Biologics generates revenue primarily from its biotechnology segment, amounting to CN¥7.46 billion. The company focuses on developing and commercializing monoclonal antibodies and other drug assets for various medical fields in China.

Innovent Biologics has demonstrated significant growth, with revenue increasing by 21.4% annually and earnings forecasted to grow by 59.8% per year. The company reported sales of ¥3.95 billion for the first half of 2024, up from ¥2.70 billion a year ago, despite a net loss of ¥392 million. Innovent's commitment to R&D is evident in their recent approval of Dupert® (fulzerasib) for NSCLC treatment, showcasing their innovative edge in precision oncology treatments and driving future growth prospects in the biotech sector.

• Navigate through the intricacies of Innovent Biologics with our comprehensive health report here.

• Gain insights into Innovent Biologics' past trends and performance with our Past report.

SEHK:1801 Revenue and Expenses Breakdown as at Sep 2024

Sichuan Kelun-Biotech Biopharmaceutical

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs to address unmet medical needs in China and internationally, with a market cap of HK$37.79 billion.

Operations: Kelun-Biotech generates revenue primarily from its pharmaceutical segment, amounting to CN¥1.88 billion. The company focuses on developing and commercializing novel drugs both in China and internationally.

Sichuan Kelun-Biotech Biopharmaceutical has shown promising growth, with revenue increasing by 24.7% over the past year to ¥1.38 billion for H1 2024 and net income reaching ¥310.23 million from a prior loss of ¥31.13 million. The company is heavily investing in R&D, as evidenced by its recent NDA acceptance for sacituzumab tirumotecan (sac-TMT) targeting NSCLC and TNBC, reflecting a robust pipeline of innovative treatments that could drive future growth. Additionally, their strategic partnership with Merck & Co., Inc., Rahway, NJ, USA to develop sac-TMT outside Greater China highlights their global ambitions and potential market expansion opportunities.

• Unlock comprehensive insights into our analysis of Sichuan Kelun-Biotech Biopharmaceutical stock in this health report.

• Review our historical performance report to gain insights into Sichuan Kelun-Biotech Biopharmaceutical's's past performance.

SEHK:6990 Earnings and Revenue Growth as at Sep 2024

Digital China Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Digital China Holdings Limited, an investment holding company, provides big data products and solutions for government and enterprise customers primarily in Mainland China, with a market cap of HK$5.44 billion.

Operations: Digital China Holdings generates revenue primarily from three segments: Big Data Products and Solutions (CN¥3.39 billion), Software and Operating Services (CN¥5.31 billion), and Traditional and Localization Services (CN¥10.03 billion). The company focuses on providing tailored solutions for government and enterprise clients in Mainland China.

Digital China Holdings has demonstrated resilience with a 5.05% increase in sales to ¥7.01 billion for H1 2024, despite heightened competition impacting net income, which dropped to ¥10.81 million from ¥40.36 million last year. The company's strategic focus on R&D is evident, with expenses accounting for 10.1% of revenue, aiming at innovation and new product lines within its non-wholly owned subsidiary DCITS, which faces competitive pressures but also potential growth avenues in software and AI sectors.

• Click here and access our complete health analysis report to understand the dynamics of Digital China Holdings.

• Gain insights into Digital China Holdings' historical performance by reviewing our past performance report.

SEHK:861 Earnings and Revenue Growth as at Sep 2024

Next Steps

• Embark on your investment journey to our 45 SEHK High Growth Tech and AI Stocks selection here.

• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.

• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1801 SEHK:6990 and SEHK:861.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com